BFM
TNGX icon

Boothbay Fund Management’s Tango Therapeutics TNGX Stock Holding History

Boothbay Fund Management’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.6M Sell
500,497
-70,853
-12% -$1.75M 0.21% 85
2026
Q1 		$12M Sell
571,350
-385,932
-40% -$5.37M 0.15% 107
2025
Q4 		$8.48M Buy
+957,282
New +$8.25M 0.13% 167
2021
Q2 		– Sell
-33,713
Closed -$375K – 2116
2021
Q1 		$375K Buy
33,713
+17,978
+114% +$207K 0.01% 1092
2020
Q4 		$180K Buy
+15,735
New +$166K 0.01% 1116

Other funds holding TNGX

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Boothbay Fund Management's TNGX Position: Q2 2026 in Review

Boothbay Fund Management reduced its Tango Therapeutics (TNGX) stake by 12% in Q2 2026, selling an estimated $1.75M and leaving 500,497 shares worth $15.6M. The position accounts for 0.21% of the portfolio, ranked #85.

Boothbay Fund Management first reported a position in TNGX in Q4 2020 and has held it in 5 quarters since. 249 funds tracked by Wall St. Rank hold TNGX as of Q2 2026.

  • Boothbay Fund Management held 500,497 shares of Tango Therapeutics worth $15.6M as of Q2 2026.
  • Boothbay Fund Management sold 70,853 Tango Therapeutics shares in Q2 2026, an estimated $1.75M.
  • Tango Therapeutics made up 0.21% of Boothbay Fund Management's portfolio in Q2 2026, its #85 holding.
  • Boothbay Fund Management first reported a position in Tango Therapeutics in Q4 2020 and has held it in 5 quarters since.
  • 249 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.